Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 4,005

Year 2022 😗

Bar-Ilan University researchers have developed a new technology that enables the use of nanoparticles to assist the body’s immune system to fight cancer.

Follow Israel Hayom on Facebook, Twitter, and Instagram

According to the research, published in the journal EMBO Molecular Medicine, the nanoparticles are used to eliminate obstacles in the malignant tumor’s environment that impede the normal activity of natural killer cells (a special sub-type of white blood cells called lymphocytes).

Read more | >

The future of physics is very bright indeed! Join us, and find out more!

Subscribe â–ș https://wmojo.com/unveiled-subscribe.

In this video, Unveiled takes a closer look at the most exciting ways that physics will change the world during YOUR lifetime! We’re now SO CLOSE to making these incredible breakthroughs, but which will happen first? And which will have the greatest impact on life, the universe, and everything?

This is Unveiled, giving you incredible answers to extraordinary questions!

Find more amazing videos for your curiosity here:
6 Scientific Breakthroughs Predicted For Your Lifetime — https://youtu.be/wGKj-3AfxdE
6 NASA Breakthroughs Predicted For Your Lifetime — https://youtu.be/EMiUmz33uJo.

0:00 Intro.

Continue reading “6 Physics Breakthroughs Predicted During Your Lifetime | Unveiled” | >

A group of scientists at Harvard Medical School are the pion-ears of innovative developments in hearing loss treatment.

Researchers at the school’s Mass Eye and Ear hospital claim to have developed a groundbreaking solution to hearing loss, one of the music community’s most vexing and elusive problems.

According to a study published in the Proceedings of the National Academy of Sciences, the researchers formulated a “drug-like cocktail” comprising various molecules that regenerate the inner ear hair cells responsible for relaying sounds to the brain.

Read more | >

Join top executives in San Francisco on July 11–12, to hear how leaders are integrating and optimizing AI investments for success. Learn More

Generative AI has received a lot of attention already this year in the tech world and beyond. Whether it’s ChatGPT’s prose or Stable Diffusion’s art, 2022 provided an insight into the potential for AI to disrupt creative industries.

But behind the headlines, 2022 brought an even more important development in AI: the rise of the vector database.

Read more | >

Join top executives in San Francisco on July 11–12, to hear how leaders are integrating and optimizing AI investments for success. Learn More

In January, new reports on Apple’s long-awaited augmented reality/virtual reality headset were released. And if what’s in these reports is even partially true, Apple is poised to give the world one of the most jaw-dropping, powerful pieces of technology in history (again) — which is why it was a bit surprising that this news didn’t make more of a splash.

This is the same company that has fans enter lotteries for tickets to corporate keynote addresses! Yet, outside of the usual tech blogs and a few newspaper columns, the future of Apple’s AR/VR device went largely unnoticed.

Read more | >

Geoffrey Hinton, a VP and engineering fellow at Google and a pioneer of deep learning who developed some of the most important techniques at the heart of modern AI, is leaving the company after 10 years, the New York Times reported today.

According to the Times, Hinton says he has new fears about the technology he helped usher in and wants to speak openly about them, and that a part of him now regrets his life’s work.

Read more | >

AI is having its moment on tech earnings calls for the second consecutive quarter, following the widely popular launch of OpenAI’s ChatGPT in late November. But not every company has the same plans for the new technology.

Nvidia (NVDA) is selling AI powered supercomputers. Microsoft (MSFT) is integrating ChatGPT into its search engine to compete with Google (GOOGL), which has its own AI searchbot.

Meta’s approach is slightly different. The core business for Meta since the early days of Facebook has been advertising sales, which still account for 98% of the company’s quarterly revenue. So naturally, enhancing advertisements with AI is where Meta believes the new technology can be most impactful.

Read more | >

Can we ensure that AI is used ethically? Will AIs themselves develop empathy and ethics? That’s the topic I’d like to discuss today. It’s important.

I recently sat down with Rana el Kaliouby, PhD, AI researcher and Deputy CEO of Smart Eye, at my private CEO Summit Abundance360 to explore these questions. Rana has been focused on this very topic for the past decade.

Think about what comprises human intelligence. It’s not just your IQ, but also your emotional and social intelligence, specifically how we relate to other people.

Read more | >

Insulin-mTOR signaling drives anabolic growth in organismal development, while its late-life antagonistic pleiotropy affects aging and compromises lifespan across animal phylogeny. Here we identify LPD-3 as a megaprotein that orchestrates the tempo of insulin-mTOR signaling during C. elegans aging. We find that an agonist insulin INS-7 is drastically over-produced and shortens lifespan in lpd-3 mutants, a C. elegans model of human Alkuraya-Kučinskas syndrome. LPD-3 forms a bridge-like tunnel megaprotein to facilitate phospholipid trafficking to plasma membrane. Lipidomic profiling reveals increased abundance of hexaceramide species in lpd-3 mutants, accompanied by up-regulation of hexaceramide biosynthetic enzymes, including HYL-1 (Homolog of Yeast Longevity). Reducing HYL-1 activity decreases INS-7 levels and rescues the shortened lifespan of lpd-3 mutants through insulin receptor/DAF-2 and mTOR/LET-363. LPD-3 antagonizes SINH-1, a key mTORC2 component, and reduces protein abundance with age in wild type animals. We propose that LPD-3 acts as a megaprotein brake for aging and its age-dependent decline restricts lifespan through the sphingolipid-hexaceramide and insulin-mTOR pathways.

The authors have declared no competing interest.

Read more | >